Chiesi Farmaceutici S.p.A., an international, research-focused biopharmaceutical group, and Gossamer Bio, a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.

Working together to develop an innovative and competitive healthcare ecosystem, by focusing on digital and healthcare innovation trends, and strengthening the research and internationalisation of the production sector. This is the aim of the collaboration agreement signed by Federated Innovation @MIND and Bioindustry Park Silvano Fumero, reference points for companies in Lombardy and Piedmont operating in the public and private health and Life Sciences sectors.

The signature of this first partnership agreement between Axxam and Lundbeck, for the identification and qualification of small molecules relevant to CNS targets, comes after more than five years of successful collaboration in assay development and High-Throughput Screening.

ICBA

May 8, 2018, 11:12 AM

Url:

http://internationalbiotech.org/

Posizione:

Tipo:

Partner

Show oldest on top

News

AGC Biologics’ Seattle Site Achieves Successful Multi-Product Inspection by U.S. Food and Drug Administration for Biologics License Applications

Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications

Agreement between Bioindustry Park and Federated Innovation @Mind to accelerate the creation of a virtual district in life science

Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide

Axxam and Lundbeck's Partnership for Lead Identification

Momentum Biotechnologies and Axxam S.p.A. Announce Collaboration to Provide Unique Drug Discovery Solutions

ICBA

7318 comments

Leave a comment

Where to find us